Clinical trial · Interventional
Study of Circulating Tumoral DNA in Ovarian Cancer
Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Ovarian Cancer
NCT01350908CI-TRIAL-00073485completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Circulating tumor DNA detection and quantification in patients with ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Blood sampling
- interventionNames
- Other: Blood sampling
Primary outcomes (1)
- measure
- Assessment and development of circulating tumor DNA detection techniques
- timeFrame
- 2 years
- description
- Quantification of circulating tumor DNA in blood samples. Results expressed in number of samples where circulating DNA is present.
Secondary outcomes (1)
- measure
- Comparison of the detection techniques (PAP (pyrophosphorolysis activated polymerisation), BEAMing, NGS(Next sequencing generation) with regards to feasibility, robustness, sensitivity and cost.
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> or = 18 years. * Patient with invasive ovarian cancer stage II to IV from FIGO classification. * Patient treated by surgery. * Patient with tumor or metastasis available for TP53 status characterization * Patient able to stand a blood collection. * Signed written informed consent approved by AFSSAPS and CPP. Exclusion Criteria: * Patient without social protection / insurance. * Borderline ovarian tumor. * Non carcinoma ovarian tumor * Patient with invasive ovarian cancer 5 years before diagnosis * Current pregnancy and lactation. * All social, medical, psychological, situations making the study impossible. * Person deprived of liberty.
References
Publications (0)
Data not yet available
No reference posted for this study.